MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) reported new clinical and translational data on agenT-797, its off-the-shelf allo-iNKT cell therapy, from a critically ill patient treated with sequential Anktiva (N-803) and agenT-797 for unresolving disseminated Coccidioides immitis, ARDS and Pseudomonas pneumonia.
Data showed pathogen suppression, lung immune restoration and tissue repair pathway activation, supporting MiNK’s ongoing randomized Phase 2 trial of agenT-797 plus standard of care in severe acute lung injury and critical illness.
Positive
- Case showed fungal and bacterial pathogen suppression after N-803 and agenT-797
- Translational data indicated reduced inflammatory signaling and tissue repair activation
- Findings support ongoing randomized Phase 2 trial in severe acute lung injury
- Prior ARDS experience linked agenT-797 with favorable safety and improved survival
- Phase 2 design includes endpoints for ventilator-free days, infections and survival
Negative
- Reported data are based on a single critically ill patient case
- Patient ultimately died following recurrent cardiac decompensation and cardiogenic shock
- Authors recommend cautious interpretation despite encouraging immune and pathogen findings
News Market Reaction – INKT
On the day this news was published, INKT gained 3.82%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Clinical data update | Positive | -6.3% | Phase 1b BOT+BAL data in refractory hepatocellular carcinoma published in Liver Cancer. |
| May 15 | Earnings and pipeline | Positive | +2.0% | Q1 2026 results plus advancement of allo‑iNKT platform and Phase 2 trial initiation. |
| May 14 | Phase 2 trial start | Positive | -4.9% | Randomized Phase 2 trial of agenT‑797 in acute lung injury and hypoxemic failure. |
| May 12 | ASGCT clinical data | Positive | +4.2% | ASGCT data showing context‑dependent immune responses and favorable safety profile. |
| May 11 | Earnings and deal | Positive | -0.8% | Agenus Q1 2026 results with higher revenue, net income, and $91M Zydus deal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions to largely positive clinical and financial news, with several constructive updates followed by negative or muted price moves.
Over the last months, MiNK and related Agenus news have centered on advancing immune-oncology and iNKT-based programs, including Phase 2 trial initiation for agenT-797 in acute lung injury and favorable ASGCT 2026 data showing context-dependent immune responses. Financial updates highlighted modest net losses and cash balances, while Agenus reported improved revenues and collaborations. Price reactions have been inconsistent, with both gains and selloffs after seemingly positive catalysts, framing today’s ATS 2026 case-based data as part of an ongoing effort to clinically validate the platform.
Key Terms
allo-inkt medical
invariant natural killer t medical
ards medical
il-15 superagonist medical
pseudomonas aeruginosa medical
cytokine medical
biomarker medical
cardiogenic shock medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial
- Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides immitis
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new clinical and translational data presented at the American Thoracic Society (ATS) International Conference 2026 and the simultaneous publication in Clinical Immunology Communications1 describing the use of sequential immunotherapy with MiNK’s off-the-shelf iNKT cell therapy, agenT-797 and N-803, an IL-15 superagonist, in a critically ill patient with unresolving disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome, and concurrent hospital-acquired Pseudomonas aeruginosa pneumonia.
The poster, titled 'Novel Invariant Natural Killer T Cell (agenT-797) and Interleukin-15 Superagonist (N-803) Combination Immunotherapy for Unresolving Coccidioides immitis Infection with Concurrent ARDS,' was presented by Terese C. Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics, and describes a sequential immunotherapy regimen pairing agenT-797, MiNK's investigational off-the-shelf iNKT cell therapy, with Anktiva® (N-803), an FDA-approved IL-15 superagonist developed by ImmunityBio, reflecting a combination strategy built on two clinically validated immune mechanisms. The patient was critically ill, facing a convergence of severe threats: disseminated Coccidioides immitis (valley fever) fungal infection, severe acute respiratory distress syndrome (ARDS), and concurrent hospital-acquired Pseudomonas aeruginosa bacterial pneumonia, all after standard-of-care antifungal, antibacterial, and supportive therapies had failed to halt clinical decline.
Key Clinical and Translational Findings
Following sequential treatment with Anktiva (N-803) and agenT-797, investigators observed:
- Suppression of both fungal and bacterial pathogens
- Active immune cell recruitment into the lung
- Reduced early inflammatory signaling
- Activation of tissue repair and immune regulatory pathways
Immune profiling revealed a coherent biological sequence: Anktiva triggered early immune activation, followed by agenT-797-driven changes consistent with iNKT cell engagement, pathogen control, and a transition from inflammation toward resolution and repair. The pattern suggests the treatment sequence may have helped restore coordinated immune function in a patient whose infection and respiratory failure had continued to progress despite intensive intervention.
“These observations are clinically and biologically important because they point to a pattern we are increasingly seeing across severe lung injury where immune failure itself may become a dominant driver of poor outcomes,” said Terese Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics. “As a practicing pulmonary critical care physician, what stands out in this case is not only the reduction in inflammatory signaling, but the evidence of immune recovery and pathogen control in a patient whose infection had persisted despite intensive antifungal, antibacterial and supportive therapy. Many critically ill patients do not decline from early inflammation alone. They deteriorate later from prolonged respiratory failure, secondary infections, immune exhaustion and multi-organ dysfunction. While this is a single case and must be interpreted with appropriate caution, the findings support the clinical question we are now studying prospectively, whether restoring immune competence can change the trajectory for patients with severe pneumonia, respiratory failure and critical illness.”
The patient's family ultimately pivoted to comfort care due to recurrent cardiac decompensation in the setting of pre-existing mitral valve disease, acute mitral regurgitation and cardiogenic shock. The authors further supported this rationale in the ATS poster presentation, when chest imaging, clinical data including real time pulmonary arterial catheter and cardiac echocardiography data augmented post-mortem cytokine and biomarker results to prioritize acute heart failure rather than cytokine release or infectious contributions as the most likely mechanism.
The ATS presentation and Clinical Immunology Communications publication build on MiNK’s prior clinical experience with agenT-797 in moderate to severe ARDS, where the therapy was associated with a favorable safety profile, improved survival rate and decreased secondary infection rates. The new findings also support MiNK’s broader platform thesis that iNKT cells may respond dynamically to the immune environment they encounter, with potential relevance across oncology, severe lung injury, persistent infection and immune dysfunction.
Expanding on these findings, MiNK recently announced the initiation of a randomized Phase 2 clinical trial evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with severe acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure due to severe pneumonia, who meet Global ARDS criteria and are admitted to the ICU. The study is designed to prospectively evaluate agenT-797 in a defined critical care population where respiratory recovery, ventilator-free days, secondary infection and survival can be assessed using clinically meaningful endpoints.
The full ATS poster will be available on the publications section of MiNK Therapeutics’ website following the presentation.
References
1 Hammond TC, et al. Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy. Clinical Immunology Communications. 2026. doi:10.1016/j.clicom.2026.04.002
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
